HK1255438A1 - 用於治疗癌症的(s，e)-3-(6-氨基吡啶-3-基)-n-((5-(4-(3-氟-3-甲基吡咯烷-l-羰基)苯基)-7-(4-氟苯基)苯并呋喃-2-基)甲基)丙烯酰胺 - Google Patents

用於治疗癌症的(s，e)-3-(6-氨基吡啶-3-基)-n-((5-(4-(3-氟-3-甲基吡咯烷-l-羰基)苯基)-7-(4-氟苯基)苯并呋喃-2-基)甲基)丙烯酰胺 Download PDF

Info

Publication number
HK1255438A1
HK1255438A1 HK18114602.1A HK18114602A HK1255438A1 HK 1255438 A1 HK1255438 A1 HK 1255438A1 HK 18114602 A HK18114602 A HK 18114602A HK 1255438 A1 HK1255438 A1 HK 1255438A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
cancer
treatment
Prior art date
Application number
HK18114602.1A
Other languages
English (en)
Chinese (zh)
Inventor
E‧巴罗格鲁
E‧巴羅格魯
S‧沙查姆
W‧塞纳佩迪斯
W‧塞納佩迪斯
Original Assignee
卡尔约药物治疗公司
卡爾約藥物治療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 卡尔约药物治疗公司, 卡爾約藥物治療公司 filed Critical 卡尔约药物治疗公司
Publication of HK1255438A1 publication Critical patent/HK1255438A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK18114602.1A 2015-08-18 2016-08-18 用於治疗癌症的(s，e)-3-(6-氨基吡啶-3-基)-n-((5-(4-(3-氟-3-甲基吡咯烷-l-羰基)苯基)-7-(4-氟苯基)苯并呋喃-2-基)甲基)丙烯酰胺 HK1255438A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562206472P 2015-08-18 2015-08-18
US62/206,472 2015-08-18
PCT/US2016/047566 WO2017031323A1 (en) 2015-08-18 2016-08-18 (s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl)-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer

Publications (1)

Publication Number Publication Date
HK1255438A1 true HK1255438A1 (zh) 2019-08-16

Family

ID=56799634

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18114602.1A HK1255438A1 (zh) 2015-08-18 2016-08-18 用於治疗癌症的(s，e)-3-(6-氨基吡啶-3-基)-n-((5-(4-(3-氟-3-甲基吡咯烷-l-羰基)苯基)-7-(4-氟苯基)苯并呋喃-2-基)甲基)丙烯酰胺

Country Status (12)

Country Link
US (1) US10363247B2 (https=)
EP (1) EP3337797A1 (https=)
JP (1) JP2018528196A (https=)
CN (1) CN108137563A (https=)
AU (1) AU2016308829A1 (https=)
CA (1) CA2995380A1 (https=)
EA (1) EA201890524A1 (https=)
HK (1) HK1255438A1 (https=)
IL (1) IL257422A (https=)
MA (1) MA42655A (https=)
MX (1) MX2018001979A (https=)
WO (1) WO2017031323A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3016946B1 (en) 2013-07-03 2022-10-12 Karyopharm Therapeutics Inc. Substituted benzofuranyl and benzoxazolyl compounds and pharmaceutical uses thereof
WO2015042414A1 (en) 2013-09-20 2015-03-26 Karyopharm Therapeutics Inc. Multicyclic compounds and methods of using same
HK1255438A1 (zh) 2015-08-18 2019-08-16 卡尔约药物治疗公司 用於治疗癌症的(s，e)-3-(6-氨基吡啶-3-基)-n-((5-(4-(3-氟-3-甲基吡咯烷-l-羰基)苯基)-7-(4-氟苯基)苯并呋喃-2-基)甲基)丙烯酰胺
WO2017117447A1 (en) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Multicyclic compounds and uses thereof
CN111171233B (zh) * 2020-01-17 2023-03-31 吉林师范大学 一种新型磁性薄层印迹膜的制备方法及用途
CN115569196B (zh) * 2020-02-26 2024-06-18 上海科技大学 多酚类物质在抗冠状病毒中的应用
CN114507215B (zh) * 2020-11-14 2024-09-13 成都海博为药业有限公司 一种作为pak4激酶抑制剂的化合物及其制备方法和应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
DE19624668A1 (de) 1996-06-20 1998-02-19 Klinge Co Chem Pharm Fab Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden
DE19818044A1 (de) 1998-04-22 1999-10-28 Klinge Co Chem Pharm Fab Verwendung von Vitamin-PP-Verbindungen
ATE345341T1 (de) 2001-07-19 2006-12-15 Pfizer Italia Srl Phenylacetamido-thiazole verbindungen, verfahren zu ihren herstellung und ihre anwendung als antitumor mittel
EP1348434A1 (en) 2002-03-27 2003-10-01 Fujisawa Deutschland GmbH Use of pyridyl amides as inhibitors of angiogenesis
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
US7078419B2 (en) 2003-03-10 2006-07-18 Boehringer Ingelheim Pharmaceuticals, Inc. Cytokine inhibitors
US7638540B2 (en) 2003-05-29 2009-12-29 The New Industry Research Organization Benzofuran compound and medicinal composition containing the same
US7420066B2 (en) 2003-08-07 2008-09-02 Bayer Pharmaceuticals Corporation Benzofuran derivatives useful for treating hyper-proliferative disorders
US7368476B2 (en) 2004-04-07 2008-05-06 Pharmacyclics, Inc. Hydroxamates as therapeutic agents
MY149038A (en) 2004-05-26 2013-07-15 Eisai R&D Man Co Ltd Cinnamide compound
TW200616613A (en) 2004-10-05 2006-06-01 Shionogi & Co Biaryl derivatives
JPWO2006054793A1 (ja) 2004-11-19 2008-06-05 財団法人新産業創造研究機構 ベンゾフラン化合物、およびそれを含有してなる医薬組成物
JP2008534664A (ja) 2005-04-06 2008-08-28 アストラゼネカ アクチボラグ 置換複素環およびｃｈｋ１、ｐｄｋ１及びｐａｋ阻害剤としてのそれらの使用
MX2007013065A (es) 2005-04-22 2008-01-14 Wyeth Corp Derivados de dihidrobenzofurano y usos de los mismos.
US20080020413A1 (en) 2006-03-29 2008-01-24 Columbia University Crystalline visfatin and methods therefor
WO2008026018A1 (en) 2006-09-01 2008-03-06 Topotarget Switzerland Sa New method for the treatment of inflammatory diseases
EP2003118A1 (de) 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Zimtsäurederivate als Modulatoren des EP2-Rezeptors
US8173677B2 (en) 2007-09-26 2012-05-08 Gemin X Pharmaceuticals Canada Inc. Compositions and methods for effecting NAD+ levels using a nicotinamide phosphoribosyl transferase inhibitor
CA2701071C (en) 2007-09-26 2018-03-27 Gemin X Pharmaceuticals Canada Inc. Compositions and methods for effecting nad+ levels using a nicotinamide phosphoribosyl transferase inhibitor
EP2098231A1 (en) 2008-03-05 2009-09-09 Topotarget Switzerland SA Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury
FR2943669B1 (fr) 2009-03-24 2011-05-06 Sanofi Aventis Derives de nicotinamide,leur preparation et leur application en therapeutique
US20130317027A1 (en) 2010-03-01 2013-11-28 Myrexis, Inc. Compounds and therapeutic uses thereof
AU2011223790A1 (en) 2010-03-01 2012-08-30 Myrexis, Inc. Compounds and therapeutic uses thereof
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
RU2017112522A (ru) 2011-05-04 2019-01-24 ФОРМА ТиЭм, ЭлЭлСИ Новые соединения и композиции для ингибирования nampt
CA2877474A1 (en) 2011-06-20 2012-12-27 Myrexis, Inc. Compounds and therapeutic uses thereof
WO2013082150A1 (en) 2011-11-30 2013-06-06 The Curators Of The University Of Missouri Small molecule inhibitors of nicotinamide phosphoribosyltransferase (nampt)
WO2014074715A1 (en) 2012-11-07 2014-05-15 Genentech, Inc. Cyclopropyl amide derivatives
WO2014085607A1 (en) * 2012-11-29 2014-06-05 Karyopharm Therapeutics Inc. Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof
WO2014111871A1 (en) 2013-01-17 2014-07-24 Aurigene Discovery Technologies Limited 4,5-dihydroisoxazole derivatives as nampt inhibitors
EP3016946B1 (en) * 2013-07-03 2022-10-12 Karyopharm Therapeutics Inc. Substituted benzofuranyl and benzoxazolyl compounds and pharmaceutical uses thereof
WO2015042414A1 (en) * 2013-09-20 2015-03-26 Karyopharm Therapeutics Inc. Multicyclic compounds and methods of using same
CA2921532A1 (en) 2013-10-09 2015-04-16 Eli Lilly And Company Novel pyridyloxyacetyl tetrahydroisoquinoline compounds useful as nampt inhibitors
US20170369470A1 (en) 2014-12-16 2017-12-28 Karyopharm Therapeutics Inc. Cyclic Compounds and Uses Thereof
EP3337796A1 (en) 2015-08-17 2018-06-27 Karyopharm Therapeutics, Inc. 3-(pyridin-3-yl)-acrylamide and n-(pyridin-3-yl)-acrylamide derivatives and their use as pak or nampt modulators
US20180244660A1 (en) 2015-08-17 2018-08-30 Karyopharm Therapeutics Inc. Cyclopropylderivatives and their use as kinase inhibitors
HK1255438A1 (zh) 2015-08-18 2019-08-16 卡尔约药物治疗公司 用於治疗癌症的(s，e)-3-(6-氨基吡啶-3-基)-n-((5-(4-(3-氟-3-甲基吡咯烷-l-羰基)苯基)-7-(4-氟苯基)苯并呋喃-2-基)甲基)丙烯酰胺
WO2017117406A1 (en) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Substituted benzofuranyl and benzoxazolyl compounds and uses thereof
WO2017117447A1 (en) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Multicyclic compounds and uses thereof

Also Published As

Publication number Publication date
MA42655A (fr) 2021-04-07
IL257422A (en) 2018-04-30
EA201890524A1 (ru) 2018-07-31
US10363247B2 (en) 2019-07-30
MX2018001979A (es) 2019-04-25
CA2995380A1 (en) 2017-02-23
EP3337797A1 (en) 2018-06-27
JP2018528196A (ja) 2018-09-27
AU2016308829A1 (en) 2018-03-08
US20180235948A1 (en) 2018-08-23
WO2017031323A1 (en) 2017-02-23
CN108137563A (zh) 2018-06-08

Similar Documents

Publication Publication Date Title
HK1255438A1 (zh) 用於治疗癌症的(s，e)-3-(6-氨基吡啶-3-基)-n-((5-(4-(3-氟-3-甲基吡咯烷-l-羰基)苯基)-7-(4-氟苯基)苯并呋喃-2-基)甲基)丙烯酰胺
MX380928B (es) Inhibidores de kras g12c.
SA518391624B1 (ar) Ror- منظمات جاما
MX2020010484A (es) Derivados de heterociclilos sustituidos como inhibidores de cdk.
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
EA201991884A3 (ru) Ингибиторы g12c kras
SG10201811384TA (en) Mnk inhibitors and methods related thereto
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
EA201691853A1 (ru) Агонисты мускариновых рецепторов
EA201001126A1 (ru) Пирролопиримидины и пирролопиридины
PH12014501157A1 (en) Pharmaceutical formulations
WO2014031438A3 (en) SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS
JOP20200086B1 (ar) مشتقات إيميدازول مكثفة بها استبدال بمجموعات هيدروكسي ثلاثية كمثبطات لـ pi3k-جاما
JOP20170104A1 (ar) مشتقات فنيل تريازول مستبدلة بأميد واستخدامها
EA201690741A1 (ru) Составы (s)-3-(4-((4-(морфолинометил)бензил)окси)-1-оксоизоиндолин-2-ил)пиперидин-2,6-диона
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
PH12017500029A1 (en) 4,5-dihydroisoxazole derivatives as nampt inhibitors
MX2016005174A (es) Composiciones para uso en la prevencion y el tratamiento de enfermedades neurodegenerativas y dolor.
NZ720879A (en) Indazole compounds as 5-ht4 receptor agonists
HK1200456A1 (en) Aryl or n-heteroaryl substituted methanesulfonamide derivatives as vanilloid receptor ligands
EA201792558A1 (ru) Противогрибковый 4-(4-(4-(((3r,5r)-5-((1h-1,2,4-триазол-1-ил)метил)-5-(2,4-дифторфенил)тетрагидрофуран-3-ил)метокси)-3-метилфенил)пиперазин-1-ил)-n-(2-гидроксициклогексил)бензамид или его фармацевтически приемлемая соль
TW201713630A (en) Substituted quinazoline compounds and methods of use thereof
MX2015015290A (es) Compuestos furanona como inhibidores de quinasa.
EA201390283A1 (ru) Модулятор киназы рецепторного типа и способы лечения поликистозной болезни почек
MA50899B1 (fr) Composés utiles pour l'inhibition de cdk7